The Combined Cost Impact: What Happens to a 25-Person Plan When You Stack Every Available Strategy

Series 09 modeled what happens to a 25-person plan when cost drivers converge: specialty drugs, pregnancy, GLP-1 utilization, MSK procedures, mental health claims amplification, and chronic disease compounding. The moderate convergence scenario pushed expected claims from $375,000 toward $450,000 to $500,000. That was the problem. This is the response. Stack domestic steering, cross-border care, international pharmacy, maternity management, MSK pathways, mental health access, SDOH intervention, and chronic disease interception on the same plan. The savings are expressed as ranges with explicit assumptions, not as point estimates. Even the conservative end of those ranges redefines the TPA value proposition for small group level funded plans.

The Baseline

#

The same 25-person employer used in the Series 09 synthesis: a small professional services firm with moderate cost driver convergence. Average age in the low 40s. Three members with chronic conditions (Type 2 diabetes, hypertension, and asthma). Two members in the 55-to-64 age bracket with higher baseline utilization. One expected pregnancy. One member on a GLP-1 medication. Expected claims fund at standard utilization: $375,000 ($15,000 per member). Under the moderate convergence scenario from LFP-09.SYN, when the specialty drug claim hits, the pregnancy is complicated, the MSK surgery proceeds at an urban hospital, and mental health conditions amplify medical spending across three members, actual claims push toward $450,000 to $500,000.

That scenario assumed no active cost management. The plan paid whatever the provider charged, at whatever facility the member chose, through whatever pharmacy channel the PBM defaulted to, with no navigation, no steering, no clinical pathway management, and no chronic disease interception. That is the baseline against which this synthesis measures the impact of an integrated cost management strategy.

Strategy-by-Strategy Impact

#

Each cost management strategy from this series applied individually to the 25-person plan, with savings expressed as a range reflecting conservative and optimistic assumptions.

Domestic steering for two qualifying elective procedures (LFP-10.03): the plan includes two members who need scheduled procedures appropriate for facility steering. One total knee replacement and one spinal injection series. Steering from an urban academic medical center to a high-quality independent ambulatory surgery center or lower-cost community hospital produces $15,000 to $30,000 per procedure in savings on the knee replacement and $3,000 to $8,000 on the injection series, based on published price transparency variation. Total domestic steering savings: $18,000 to $38,000.

Cross-border care for one qualifying procedure (LFP-10.04): one member elects a dental implant procedure at a JCI-accredited facility in Mexico rather than a US provider. Full-mouth dental work at $3,000 to $5,000 internationally versus $12,000 to $18,000 domestically, including travel and lodging. Total cross-border savings: $7,000 to $13,000. If the qualifying procedure were orthopedic rather than dental, the savings would be substantially larger ($20,000 to $35,000), but the conservative estimate uses the more common dental scenario.

International pharmacy for two high-cost drug members (LFP-10.05): two members on chronic brand-name medications where Canadian pharmacy pricing offers 30% to 50% savings. If combined annual US drug cost for both members is $24,000 and international pharmacy reduces that cost by 30% to 50%, savings range from $7,200 to $12,000. Legal complexity and member acceptance reduce the probability of full utilization. Probability-adjusted savings: $4,000 to $8,000.

Maternity management for one pregnancy (LFP-10.07): the plan includes one expected delivery. A maternity management program that includes early risk stratification, care coordination, and facility steering reduces the probability of preventable complications and directs the delivery to a lower-cost facility when clinically appropriate. Uncomplicated vaginal delivery at a steered facility versus unmanaged delivery at a high-cost urban hospital produces $3,000 to $8,000 in savings. If the pregnancy has complications that the management program helps manage (preterm birth prevention, preeclampsia monitoring), avoided NICU days and complication management produce savings of $15,000 to $50,000. Weighted across the probability distribution, maternity management savings: $5,000 to $25,000.

MSK pathways for three MSK members (LFP-10.08): three members present with MSK conditions (low back pain, knee osteoarthritis, shoulder injury). Virtual physical therapy enrollment reduces surgical candidacy by 40% to 60% in published studies. Surgical second opinion changes the treatment plan in 30% to 50% of reviewed cases. For the three MSK members: if one avoids surgery entirely through virtual PT ($25,000 to $50,000 avoided procedure), one is redirected from surgery to conservative care through second opinion ($25,000 to $40,000 avoided procedure), and the third proceeds to surgery but at a steered facility (30% to 50% savings on the procedure). Combined MSK pathway savings: $15,000 to $40,000.

Mental health access and SDOH intervention (LFP-10.09): improved mental health access through an evidence-based platform and SDOH screening with community resource routing. Three members benefit from improved access (one avoids an emergency department visit through earlier therapy engagement, one improves chronic disease management through SDOH resource connection, one avoids behavioral health crisis through timely intervention). Individual savings are moderate ($2,000 to $5,000 per member). Combined mental health and SDOH savings: $5,000 to $15,000.

Chronic disease interception for two members on deteriorating trajectories (LFP-10.10): two members with worsening chronic condition indicators (rising A1c, declining medication adherence) are enrolled in a digital chronic disease management program. The program stabilizes their conditions and avoids progression to high-cost complications. Savings are partially current-year (reduced emergency utilization, improved medication adherence reducing acute events) and partially future-year (avoided nephropathy, avoided cardiovascular event). Current-year savings: $5,000 to $15,000. Future-year avoided claims: $10,000 to $30,000. Total interception savings including future-year impact: $15,000 to $45,000, of which approximately $5,000 to $15,000 is realized in the current plan year.

GLP-1 cost management (LFP-10.10): one member on a GLP-1 medication. Pharmacy channel optimization and international pharmacy access reduce annual drug cost from $16,000 to $10,000 to $12,000. Prior authorization and step therapy prevent a second member from accessing GLP-1 without clinical justification. Outcomes tracking ensures the enrolled member is responding to treatment, justifying continued coverage. GLP-1 management savings: $4,000 to $6,000 in current-year pharmacy cost reduction, plus downstream medical cost reduction from effective weight management.

Gross Savings Range

#

Adding the individual strategy savings:

Domestic steering: $18,000 to $38,000. Cross-border care: $7,000 to $13,000. International pharmacy: $4,000 to $8,000. Maternity management: $5,000 to $25,000. MSK pathways: $15,000 to $40,000. Mental health access and SDOH: $5,000 to $15,000. Chronic disease interception (current-year): $5,000 to $15,000. GLP-1 cost management: $4,000 to $6,000.

Total gross savings range: $63,000 to $160,000.

The wide range reflects legitimate uncertainty. The conservative end assumes lower savings per strategy, lower member participation, and excludes future-year chronic disease savings. The optimistic end assumes favorable scenarios across multiple strategies with strong member engagement. The midpoint of the range, approximately $110,000, represents a plausible scenario for a plan that implements all strategies competently and achieves moderate member participation.

Net-of-Implementation-Cost Range

#

Implementation costs for the full strategy stack across a 25-person plan include vendor fees for virtual PT and MSK management ($3,000 to $6,000 annually), mental health platform ($900 to $2,400), SDOH data and navigation ($1,200 to $4,500), chronic disease management vendor ($4,800 to $14,400 for enrolled members), maternity management program ($1,500 to $3,000), member navigation and care coordination ($5,000 to $12,000 for a fractional care coordinator or vendor contract), pharmacy optimization and GLP-1 management (largely embedded in PBM relationship, incremental cost $1,000 to $3,000), benefit redesign and plan document updates ($2,000 to $5,000 one-time, amortized), and claims analytics infrastructure ($2,000 to $5,000 annually).

Total implementation cost: approximately $21,400 to $55,300 annually.

Net savings range: $63,000 minus $55,300 at the conservative end (approximately $7,700) to $160,000 minus $21,400 at the optimistic end (approximately $138,600).

The conservative scenario produces a modest net positive. The optimistic scenario produces savings exceeding 30% of the expected claims fund. The midpoint, net savings of approximately $55,000 to $70,000, represents 15% to 19% of the $375,000 expected claims fund.

Sensitivity Analysis

#

The most uncertain inputs and their impact on the range merit explicit examination.

Cross-border care member acceptance is the most uncertain variable. If no member is willing to travel internationally for care (a reasonable possibility in many populations), cross-border savings drop to zero. Removing cross-border care from the stack reduces gross savings by $7,000 to $13,000, a meaningful but not fatal reduction.

International pharmacy legal risk creates uncertainty about sustainability. Federal importation law technically prohibits the practice, and enforcement posture could change. Removing international pharmacy reduces gross savings by $4,000 to $8,000.

Maternity management variance is driven by a single binary outcome: whether the pregnancy is complicated or uncomplicated. An uncomplicated pregnancy produces modest management savings. A complicated pregnancy produces large savings. On a single plan with one pregnancy, the outcome is binary, not probabilistic. Across a TPA’s book of 200 plans, the law of large numbers applies and the expected value becomes meaningful.

Chronic disease interception timing creates measurement uncertainty. If enrolled members avoid complications in year two rather than year one, the current-year savings are lower but the strategy remains positive over the two-year measurement window.

The strategies with the strongest evidence base are MSK pathways (published outcomes from Hinge Health, Sword Health, Omada Health showing consistent surgery reduction and cost savings) and mental health access (JAMA-published ROI data from Spring Health, Aon-validated cost reduction from Lyra Health). Even if the geographic arbitrage strategies are excluded entirely (no cross-border care, no international pharmacy), the clinical pathway strategies, MSK management, mental health access, chronic disease interception, maternity management, domestic steering, and GLP-1 management, produce gross savings of $52,000 to $139,000 against implementation costs of approximately $18,000 to $50,000. The net positive remains.

The Redefined Value Proposition

#

The difference between a TPA that processes claims and a TPA that deploys this full strategy stack is not an incremental improvement in operational efficiency. It is a different business. The claims-processing TPA earns $15 to $30 per employee per month in administrative fees and competes on price and service responsiveness. The cost management TPA earns administrative fees plus a share of the savings it produces, competes on demonstrated financial impact, and creates switching costs that make broker-driven displacement difficult.

The margin structure changes. A TPA managing 5,000 covered lives at $20 PEPM generates $1.2 million in annual administrative revenue. The same TPA that generates $200 PMPY (per member per year) in net claims savings across those 5,000 lives creates $1 million in annual value for its employer clients, value that justifies performance-based compensation above the base administrative fee. The competitive moat widens because the cost management infrastructure (vendor relationships, claims analytics, member navigation capability, benefit design expertise) takes years to build and cannot be replicated by a competitor dropping its administrative fee by $2 PEPM.

The value proposition to each stakeholder changes. For employers: the TPA is not an administrative vendor. It is a cost management partner whose performance directly impacts the employer’s health benefits expense. For brokers: the TPA provides quantifiable outcomes that the broker can present at renewal, strengthening the broker’s own client relationship. For stop loss carriers: the TPA’s cost management reduces claims exposure, improving loss ratios and justifying preferred pricing. A stop loss carrier evaluating two TPAs, one that processes claims and one that actively manages cost, has a financial incentive to offer better terms to the cost-managing TPA.

This is the bridge to Series 15. The product architecture that Series 15 proposes to build (LFP-15.01) is predicated on the cost management capability this series has mapped. The tiered model that distinguishes Core (standard claims processing), Plus (cost-aware administration), and Black (full cost management integration) reflects the spectrum between the floor described in LFP-10.01 and the ceiling modeled in this synthesis. The magnitude of the combined opportunity, even at the conservative end of the range, justifies the investment in building the capability. The question is not whether a TPA should build it. The question is how fast.